302 related articles for article (PubMed ID: 36267871)
1. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis.
Overi D; Carpino G; Cristoferi L; Onori P; Kennedy L; Francis H; Zucchini N; Rigamonti C; Viganò M; Floreani A; D'Amato D; Gerussi A; Venere R; Alpini G; Glaser S; Alvaro D; Invernizzi P; Gaudio E; Cardinale V; Carbone M
JHEP Rep; 2022 Nov; 4(11):100556. PubMed ID: 36267871
[TBL] [Abstract][Full Text] [Related]
2. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
Kennedy L; Carpino G; Owen T; Ceci L; Kundu D; Meadows V; Kyritsi K; Franchitto A; Onori P; Isidan A; Zhang W; Ekser B; Alvaro D; Gaudio E; Gershwin ME; Francis H; Glaser S; Alpini G
J Hepatol; 2023 Jan; 78(1):99-113. PubMed ID: 35987275
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
[TBL] [Abstract][Full Text] [Related]
4. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis.
Cazzagon N; Sarcognato S; Floreani A; Corrà G; De Martin S; Guzzardo V; Russo FP; Guido M
JHEP Rep; 2021 Jun; 3(3):100286. PubMed ID: 34041468
[TBL] [Abstract][Full Text] [Related]
6. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.
Iruzubieta P; Goikoetxea-Usandizaga N; Barbier-Torres L; Serrano-Maciá M; Fernández-Ramos D; Fernández-Tussy P; Gutiérrez-de-Juan V; Lachiondo-Ortega S; Simon J; Bravo M; Lopitz-Otsoa F; Robles M; Ferre-Aracil C; Varela-Rey M; Elguezabal N; Calleja JL; Lu SC; Milkiewicz M; Milkiewicz P; Anguita J; Monte MJ; Marin JJG; López-Hoyos M; Delgado TC; Rincón M; Crespo J; Martínez-Chantar ML
JHEP Rep; 2021 Jun; 3(3):100276. PubMed ID: 33997750
[TBL] [Abstract][Full Text] [Related]
7. Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis.
Zhu YJ; Li J; Liu YG; Jiang Y; Cheng XJ; Han X; Wang CY; Li J
World J Gastroenterol; 2023 Sep; 29(34):5075-5081. PubMed ID: 37753365
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital.
Taneja S; Mehtani R; De A; Mitra S; Rathi S; Verma N; Premkumar M; Minz R; Duseja A; Das A; Singh V; Dhiman RK; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):241-251. PubMed ID: 36950480
[TBL] [Abstract][Full Text] [Related]
11. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.
Colapietro F; Gershwin ME; Lleo A
J Transl Autoimmun; 2023; 6():100188. PubMed ID: 36684809
[TBL] [Abstract][Full Text] [Related]
12. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
14. Increased p16
Sasaki M; Sato Y; Nakanuma Y
J Autoimmun; 2020 Feb; 107():102377. PubMed ID: 31812332
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
16. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
[TBL] [Abstract][Full Text] [Related]
18. Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis.
Yamashita Y; Umemura T; Kimura T; Joshita S; Hirohara J; Nakano T; Komori A; Tanaka A
JHEP Rep; 2023 Apr; 5(4):100662. PubMed ID: 36873419
[TBL] [Abstract][Full Text] [Related]
19. Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis.
Sánchez-Muñoz D; Castellano-Megías VM; Romero-Gómez M
Dig Liver Dis; 2007 Mar; 39(3):262-6. PubMed ID: 17270507
[TBL] [Abstract][Full Text] [Related]
20. A rare coexistence of sarcoidosis with overlap syndrome and sarcoidosis with primary biliary cholangitis and Sjogren's syndrome: Two distinct case reports.
Bougacha M; Blibech H; Bouchabou B; Jouini R; Helal I; Snene H; Belkhir D; Mehiri N; Ennaifer R; Chedly A; Ben Salah N; Louzir B
Heliyon; 2024 Feb; 10(4):e25826. PubMed ID: 38390068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
